Chronic Lymphocytic Leukemia | Specialty

Dr. Rogers on the Next Steps With Obinutuzumab/Ibrutinib/Venetoclax in CLL

April 12th 2021

Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Barr on the Next Steps With Umbralisib/Ublituximab/Venetoclax in CLL

April 9th 2021

Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.

Pirtobrutinib Showcases Encouraging Activity in CLL, MCL, and Other B-Cell Malignancies

April 8th 2021

Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.

Dr. Barr on the Safety Profile of Umbralisib/Ublituximab/Venetoclax in CLL

April 8th 2021

Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.

Dr. Shadman on Considerations for BTK inhibitors in CLL

April 7th 2021

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLL

April 6th 2021

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Dr. Shadman on Continuous Vs Time-Limited Treatments in CLL

April 2nd 2021

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

Duvelisib Granted Positive EU Opinion for Relapsed/Refractory CLL and Refractory Follicular Lymphoma

April 1st 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

Rolling Submission of BLA to FDA Completed for Ublituximab/Umbralisib in CLL

March 29th 2021

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

Dr. Mead on the Role of BTK Inhibition After Venetoclax in Relapsed/Refractory CLL

March 12th 2021

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.

x